Talon Therapeutics Appoints Elizabeth Weatherman to Board of Directors

Talon Therapeutics Appoints Elizabeth Weatherman to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Talon
Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and
efficient clinical development of product candidates targeting hematologic
malignancies and solid tumors, as well as a product candidate for the
treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer
therapeutics, today announced the appointment of Elizabeth (Bess) Weatherman
to the Company's Board of Directors.Ms. Weatherman is a Managing Director of
Warburg Pincus and leads the firm's investment activity in the healthcare
sector. Warburg Pincus is the majority shareholder of Talon.

The Company also announced the resignation from the Board of Jonathan Leff,
formerly a Managing Director at Warburg Pincus. Mr. Leff left Warburg Pincus
to join Deerfield Management, Talon's second largest investor.

"We are delighted to welcome Bess to our Board of Directors during this
critical stage in the Company's evolution.With more than 20 years investing
and advising in the healthcare sector, Bess brings superior strategic insight
and extensive industry relationships to the Board.With the accelerated
approval of Marqibo®, the Company is now addressing important strategic
commercialization choices and Bess will play a key role in guiding the
Company's decisions," stated Leon Rosenberg M.D. and Chairman of the Board of
Directors of Talon Therapeutics.

Steven Deitcher M.D., President, CEO and Board Member of Talon Therapeutics
added, "We also want to thank Jonathan Leff for his excellent service on the
Talon Board and wish him well at Deerfield."

"I am pleased to join Talon's Board of Directors," stated Ms. Weatherman.
"Marqibo's approved indication addresses an important, underserved hematologic
malignancy. I look forward to working closely with Talon's Board and
management team."

Ms. Weatherman joined Warburg Pincus in 1988 and leads the firm's investment
activities in the healthcare sector, an area in which she helped build the
firm's domain expertise. Ms. Weatherman also serves on the board of directors
of Bausch & Lomb, Constitution Medical, International Technidyne Corp., JHP
Pharmaceuticals, ReSearch Pharmaceutical Services, Silk Road Medical, and
Tornier. Ms. Weatherman received a B.A. summa cum laude in English from Mount
Holyoke College and holds an M.B.A. from the Stanford Graduate School of

About Talon Therapeutics

Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing
upon medical opportunities, efficiently and expertly leading product
candidates through clinical development, and transferring value to patients,
patient care providers, shareholders, corporate partners, and employees.

In addition to Marqibo, Talon has additional pipeline opportunities some of
which, like Marqibo, have the potential to improve delivery and enhance the
therapeutic benefits of well characterized, proven chemotherapies and enable
high potency dosing without increased toxicity.

Additional information on Talon Therapeutics can be found at www.talontx.com.

The Talon Therapeutics, Inc. logo is available at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements are
often, but not always, made through the use of words or phrases such as
"anticipates," "expects," "plans," "believes," "intends," and similar words or
phrases. These forward-looking statements include without limitation,
statements regarding Talon's commercialization strategies for Marqibo. Such
statements involve risks and uncertainties that could cause Talon's actual
results to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are based on
current expectations, forecasts and assumptions that are subject to risks and
uncertainties, which could cause actual outcomes and results to differ
materially from these statements. Such risks and uncertainties include:
Talon's lack of experience commercializing pharmaceutical products; that Talon
will be able to secure the additional capital necessary to fund
commercialization activities for Marqibo, as well as its ongoing research and
development programs to completion; Talon's reliance on third-party
researchers to develop its product candidates, and its lack of experience in
developing pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-K for the year ended December 31, 2011 and
its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.
Talon assumes no obligation to update these statements, except as required by

CONTACT: Corporate
         Talon Therapeutics, Inc.
         Investor Relations Team
         (650) 588-6641

Talon Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.